Healthy Skepticism Library item: 14651
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: news
Sales Through Retail Pharmacies (Twelve months to September 2008)
IMS Health 2008 Nov 22
http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Retail_Drug_Monitor_11_08.pdf
Full text:
NORTH AMERICA $225.4 billion up 2%
U.S.A. $208.1 billion up 1%
CANADA $17.2 billion up 7%
EUROPE (TOP 5) $117.3 billion up 3%
GERMANY $35.9 billion up 5%
FRANCE $31.4 billion up 2%
UK $16.7 billion down 2%
ITALY $17.6 billion up 2%
SPAIN $15.6 billion up 6%
JAPAN (including hospitals) $65.4 billion up 4%
LATIN AMERICA (TOP 3) $24.8 billion up 10%
BRAZIL $12.7 billion up 12%
MEXICO $8.9 billion up 4%
ARGENTINA $3.1 billion up 22%
AUSTRALIA/NZ $8.2 billion up 11%
The top 5 therapy classes at ATC3 level in the 12 months to September
2008 were:
1. C10A – Cholesterol & trigly. regulators
2. A2B – Antiulcerants
3. N6A – Antidepressants & mood stabilisers
4. N5A – Antipsychotics
5. N3A – Anti-epileptics
The top 5 products in the 12 months to September 2008 were:
1. Lipitor
2. Plavix
3. Nexium
4. Seretide/Advair
5. Enbrel
The top 5 corporations in the 12 months to September 2008 were:
1. Pfizer
2. GlaxoSmithKline
3. Novartis
4. AstraZeneca
5. Sanofi-Aventis
